Human Erythroid Progenitor Cell Line for B19 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and producing infectious parvovirus B19 particles are hindered by the lack of suitable cell lines, with existing cell lines being either non-permissive or inefficient, and existing detection methods fail to accurately assess infectivity due to low sensitivity and instability.
Innovation Solution
Development of novel human erythroid progenitor cell lines that are highly permissive and sensitive to B19 infection, characterized by low expression of GM-CSF-R and high expression of Epo-R, allowing for efficient and reliable production and detection of infectious B19 particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cell lines (UT-7/Epo-S1, KU812, TF-1) are used for B19 detection and production, then the process is established and reproducible, but the permissivity to B19 infection is low and sensitivity is insufficient
Solution Approach 1:
The patent modifies cellular parameters by selecting and characterizing cell lines based on specific receptor expression profiles (high CD36, high Integrin α5, low GM-CSF-R). This parameter-based selection identifies cells with optimal permissivity to B19 infection, resolving the contradiction between established reliability and detection sensitivity.
2Measurement precision
If primary CD36+ erythroid progenitor cells are used, then high permissivity to B19 infection is achieved, but the cells are unstable and difficult to maintain
Solution Approach 1:
The patent creates stable cell line copies (UT-7/Epo-S1, KU812, TF-1, and primary CD36+ EPCs) that replicate the essential functional characteristics needed for B19 detection. These cell line copies provide a stable, reproducible alternative to primary cells while maintaining the necessary permissivity through selective characterization and cultivation protocols.
3Ease of operation
If NAT (Nucleic Acid Testing) is used for B19 detection, then the method is widely available and easy to perform, but it cannot assess infectious particles and DNA quantification is inadequate
Solution Approach 1:
The patent introduces permissive cell lines as an intermediary system between NAT and direct infectivity assessment. Cells infected with B19 serve as a bridge: they take up viral particles from the sample, amplify the signal through productive infection, and enable detection of infectious particles via cytopathic effects or viral production, thereby overcoming the limitations of direct NAT while maintaining operational feasibility.
4Ease of manufacture
If animal parvoviruses (CPV, PPV) are used to evaluate viral reduction procedures, then the models are available and can be used for industrial procedures, but the physicochemical characteristics and behaviours are not identical between species
Solution Approach 1:
The patent applies local quality by using human erythroid progenitor cell lines with specific receptor expression profiles (high CD36, high Integrin α5) that create a localized environment optimized for human B19 virus interaction. This localized cellular environment provides species-specific accuracy for evaluating viral reduction procedures while maintaining the practical advantages of established cell culture systems.
Data Source
AI summary
The present invention concerns a novel human erythroid progenitor cell line, wherein at least 90% of the cells are CD36+ CD44−CD71+; and wherein the cells:—do not express the gene encoding the receptor of Granulocyte-macrophage colony-stimulating factor (GM-CSF-R gene) or express GM-CSF-R gene at a lower level than the cells of human UT-7/Epo-S1 cell line; and—express the gene encoding the receptor of erythropoietin (Epo-R gene). The present invention also concerns the uses thereof for producing, detecting, or quantifying parvovims B19. The present invention allows the use of the cell lines for 1) a highly sensitive B19 infectious particles detection, and, 2) the efficient production of infectious B19 particles.